Lunit

Lunit EBITDA per Share

The EBITDA per Share of Lunit (328130.KQ) as of Oct 17, 2026 is 1.62 KRW. In the previous year, EBITDA per Share was -2.29 KRW — a change of -170.55% (higher).

EBITDA per Share

1.62KRW

YoY

-170.55%

Last updated:

EBITDA per Share of Lunit is 2024 1.62 KRW. EBITDA per Share of Lunit was 2023 -2.29 KRW. It decreases by -170.55% higher compared to the previous year.

The Lunit EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-1,102.51 KRW
Jan 1, 2020
-901.98 KRW
Jan 1, 2021
-1,943.79 KRW
Jan 1, 2022
0.28 KRW
Jan 1, 2023
-2.29 KRW
Jan 1, 2024
1.62 KRW
The Lunit EBITDA per Share history
YEAREBITDA per ShareYoY
1.62KRW-170.55%
-2.29KRW-906.78%
0.28KRW-100.01%
-1,943.79KRW+115.50%
-901.98KRW-18.19%
-1,102.51KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

EBITDA per Share of Lunit is 1.62 KRW in 2024.

EBITDA per Share of Lunit changed from -2.29 KRW to 1.62 KRW, representing a -170.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Lunit since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lunit

All Key Metrics — Lunit